KR20140017513A - 아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법 - Google Patents

아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법 Download PDF

Info

Publication number
KR20140017513A
KR20140017513A KR1020137016719A KR20137016719A KR20140017513A KR 20140017513 A KR20140017513 A KR 20140017513A KR 1020137016719 A KR1020137016719 A KR 1020137016719A KR 20137016719 A KR20137016719 A KR 20137016719A KR 20140017513 A KR20140017513 A KR 20140017513A
Authority
KR
South Korea
Prior art keywords
seq
ser
antibody
thr
apoe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137016719A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 홀츠만
정수 김
홍 지앙
아담 엘토라이
Original Assignee
워싱톤 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워싱톤 유니버시티 filed Critical 워싱톤 유니버시티
Publication of KR20140017513A publication Critical patent/KR20140017513A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020137016719A 2010-12-02 2011-12-02 아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법 Withdrawn KR20140017513A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US61/419,060 2010-12-02
US201161548542P 2011-10-18 2011-10-18
US61/548,542 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
KR20140017513A true KR20140017513A (ko) 2014-02-11

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137016719A Withdrawn KR20140017513A (ko) 2010-12-02 2011-12-02 아밀로이드 플라크 관련 증상을 치료하는 조성물과 방법

Country Status (14)

Country Link
US (2) US20140037638A1 (cg-RX-API-DMAC10.html)
EP (1) EP2646053A4 (cg-RX-API-DMAC10.html)
JP (1) JP2014502276A (cg-RX-API-DMAC10.html)
KR (1) KR20140017513A (cg-RX-API-DMAC10.html)
CN (1) CN103338786A (cg-RX-API-DMAC10.html)
AU (1) AU2011336360A1 (cg-RX-API-DMAC10.html)
BR (1) BR112013013723A2 (cg-RX-API-DMAC10.html)
CA (1) CA2819679A1 (cg-RX-API-DMAC10.html)
MX (1) MX2013006116A (cg-RX-API-DMAC10.html)
NZ (1) NZ611614A (cg-RX-API-DMAC10.html)
RU (1) RU2013130002A (cg-RX-API-DMAC10.html)
SG (1) SG190952A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012075422A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201303996B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
BR112017006419A2 (pt) 2014-09-30 2017-12-19 Univ Washington medições cinéticas de tau
WO2017192711A1 (en) * 2016-05-03 2017-11-09 University Of South Florida Compositions and methods of modulating abeta protein
AU2017350947B2 (en) * 2016-10-28 2024-02-15 Washington University Anti-ApoE antibodies
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
AU2020282792B2 (en) * 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
WO2023069892A1 (en) * 2021-10-19 2023-04-27 Short Jay M Conditionally active proteins for neurodegenerative diseases
AU2023399623A1 (en) * 2022-11-30 2025-07-03 Bio-Techne Corporation Natural killer cell engagers
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142300C (en) * 1992-10-13 2005-08-23 Allen D. Roses Methods for detecting alzheimer's disease
WO2005051998A2 (en) * 2003-11-28 2005-06-09 Astrazeneca Ab Antibodies binding to a c-terminal fragment of apolipoprotein e
EP1736162A1 (en) * 2004-03-30 2006-12-27 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
EP1991252A2 (en) * 2006-02-21 2008-11-19 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CA2791648A1 (en) * 2010-03-01 2011-09-09 The J. David Gladstone Institutes Antibody specific for apolipoprotein and methods of use thereof

Also Published As

Publication number Publication date
WO2012075422A2 (en) 2012-06-07
US20160355581A1 (en) 2016-12-08
CN103338786A (zh) 2013-10-02
ZA201303996B (en) 2015-10-28
EP2646053A4 (en) 2014-05-28
AU2011336360A1 (en) 2013-07-04
SG190952A1 (en) 2013-07-31
NZ611614A (en) 2015-07-31
EP2646053A2 (en) 2013-10-09
WO2012075422A3 (en) 2012-10-04
MX2013006116A (es) 2013-10-17
CA2819679A1 (en) 2012-06-07
JP2014502276A (ja) 2014-01-30
US20140037638A1 (en) 2014-02-06
BR112013013723A2 (pt) 2019-09-24
RU2013130002A (ru) 2015-01-10

Similar Documents

Publication Publication Date Title
CN114430744B (zh) 抗Tau抗体及其用途
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
US20160355581A1 (en) Compositions and methods for treating amyloid plaque associated symptoms
CN106456766B (zh) 抗免疫原性糖肽的抗体、包含其的组合物及其用途
CN1703426B (zh) 识别β-淀粉样肽的人源化抗体
KR100996936B1 (ko) 베타 아밀로이드 펩티드를 인식하는 인간화된 항체
CN117024583A (zh) 抗N3pGlu淀粉状蛋白β肽抗体及其用途
CA2761665A1 (fr) Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide
SG185277A1 (en) Humanized antibody
JP2020506162A (ja) 抗ａｐｏｅ抗体
KR20190109575A (ko) 녹내장의 치료를 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
WO2019201133A1 (zh) 神经生长因子的单克隆抗体及其编码基因和应用
JP2003523764A (ja) Ａβペプチドを隔離するヒト化抗体
KR20100097651A (ko) 베타-아밀로이드 펩티드에 특이적인 신규 항체 및 진단제 또는 진단약으로서의 그 용도
JP6952888B2 (ja) 抗ｐａｃａｐ抗体
US20140127225A1 (en) Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
US10556947B2 (en) Binding molecule that binds specifically to the precursor of brain-derived neurotrophic factor
CN113508131B (zh) 人源化抗Aβ单克隆抗体及其应用
CN112513088A (zh) 抗ox40抗体、其抗原结合片段及其医药用途
CN115175932B (zh) 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
WO2016127912A1 (zh) Pcsk9抗体、其药物组合物及其用途
RU2716101C2 (ru) Антитело к склеростину, его антигенсвязывающий фрагмент и медицинское применение
US12509512B2 (en) Semaphorin 3A antibodies and uses thereof
CN118165108A (zh) 抗猫pd-1单克隆抗体及其应用
TW202216760A (zh) 抗類澱粉β (ABETA)抗體

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130627

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid